Zobrazeno 1 - 10
of 149
pro vyhledávání: ''
Publikováno v:
The Journal of Infectious Diseases. 225:1773-1776
Background Limited evidence exists on efficacy and tolerability of quinacrine for nitroimidazole-refractory giardiasis. Methods Nitroimidazole-refractory giardiasis cases, defined as microbiologically (microscopy and/or PCR) confirmed treatment failu
Autor:
Matthew D. Zimmerman, Elise D Pieterman, Han Wang, Lina Keutzer, Ulrika S. H. Simonsson, Aart van der Meijden, Hannelore I. Bax, Jurriaan E. M. de Steenwinkel, Sanne van den Berg
Publikováno v:
J Infect Dis
Journal of Infectious Diseases, 224(6), 1039-1047. Oxford University Press
Journal of Infectious Diseases, 224(6), 1039-1047. Oxford University Press
Background The treatment success rate of drug-resistant (DR) tuberculosis is alarmingly low. Therefore, more effective and less complex regimens are urgently required. Methods We compared the efficacy of an all oral DR tuberculosis drug regimen consi
Autor:
James S. McCarthy, Rebecca E. Watts, Maria Rebelo, David S. Khoury, Zuleima Pava, Hayley Mitchell, Lachlan Webb, Rebecca Pawliw, Miles P. Davenport, Jeremy Gower
Publikováno v:
The Journal of Infectious Diseases. 223:2154-2163
Background Artemisinin derivatives are the leading class of antimalarial drugs due to their rapid onset of action and rapid clearance of circulating parasites. The parasite clearance half-life measures the rate of loss of parasites from blood after t
Autor:
Christopher L. Peatey, Qin Cheng, Rebecca E. Watts, Paul J. Pickering, Michelle L. Gatton, James S. McCarthy, Nanhua Chen, Karen Anderson, Karryn Gresty
Publikováno v:
The Journal of Infectious Diseases. 223:1631-1638
Background Artemisinin monotherapy of Plasmodium falciparum infection is frequently ineffective due to recrudescence. Artemisinin-induced dormancy, shown in vitro and in animal models, provides a plausible explanation. To date, direct evidence of art
Autor:
Donald D. Anthony, Ashwin Balagopal, Carey L. Shive, David L. Wyles, Sofi Damjanovska, Corinne Kowal, Laura M. Smeaton, Beverly Alston-Smith, Mark S. Sulkowski, Daniel E. Cohen, Debika Bhattacharya
Publikováno v:
J Infect Dis
BackgroundHepatitis C virus (HCV) direct-acting antivirals are highly effective. Less is known about changes in markers of immune activation in persons with human immunodeficiency virus (HIV) in whom a sustained virologic response (SVR) is achieved.M
Autor:
Harel Dahari, Michio Imamura, Evan Gorstein, Susan L. Uprichard, Kazuaki Chayama, Swikriti Dasgupta, Masataka Tsuge, Takashi Nakahara, Scott J. Cotler, Alexander Churkin, David Yardeni, Danny Barash, Ohad Etzion
Publikováno v:
J Infect Dis
We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy can shorten hepatitis C virus treatment duration with sofosbuvir-velpatasvir, elbasvir-grazoprevir, and sofosbuvir-ledipasvir without compromising ef
Publikováno v:
J Infect Dis
Background Chronic inflammation in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection increases cognitive impairment. With newer, direct-acting antiviral therapies for HCV, our objective was to determine whether chronic inflammati
Autor:
Scott Letendre, Vikas Misra, Dana Gabuzda, Sukrutha Chettimada, Kiana Keller, Susan Morgello, Robert A. Parker, Ronald J. Ellis, David R. Lorenz, Shibani S. Mukerji
Publikováno v:
The Journal of Infectious Diseases
The Journal of infectious diseases, vol 223, iss 9
The Journal of infectious diseases, vol 223, iss 9
Background The prevalence and mortality risk of depression in people with human immunodeficiency virus (HIV) infection receiving antiretroviral therapy (ART) is higher than in the general population, yet biomarkers for therapeutic targeting are unkno
Autor:
William F. McCarthy, Donna Tosh, Kristopher M Paolino, Meshell N Morrison, James E Moon, Sean R Marcsisin, Jason W. Bennett, Christian A Darko, Qigui Li, Patrick Twomey, Philip L Smith, Brittney M Potter, Gregory A Reichard, Susan B Cicatelli, Brandon S Pybus, Kristin T Mills, Jeffrey W Froude, Thomas G Oliver, Michele D. Spring, Norman C. Waters, Jason C Sousa
Publikováno v:
The Journal of Infectious Diseases
BackgroundPlasmodium vivax malaria requires a 2-week course of primaquine (PQ) for radical cure. Evidence suggests that the hepatic isoenzyme cytochrome P450 2D6 (CYP2D6) is the key enzyme required to convert PQ into its active metabolite.MethodsCYP2
Autor:
Laura Zamorano, Isabel M. Barcelo, Antonio Oliver, Gabriel Torrens, Carlos Juan, Elena Jordana-Lluch, Irina Sánchez-Diener
Publikováno v:
The Journal of Infectious Diseases. 220:1729-1737
Background Searching for new strategies to defeat Pseudomonas aeruginosa is of paramount importance. Previous works in vitro showed that peptidoglycan recycling blockade disables AmpC-dependent resistance and enhances susceptibility against cell-wall